Abstract
Breast cancer (BCa) is one of the common malignancies among women. Doxorubicin (Dox), a type of anthracycline anti-tumor drug, is a first-line chemotherapy drug for BCa. It is badly needed to effectively reverse BCa resistance to Dox and improve the clinical symptoms of BCa. Chromatin Modification protein 4C (CHMP4C) is a subunit of the endosomal sorting complex and is expressed in the nucleus and cytoplasm. CHMP4C has been shown to be overexpressed in multiple types of cancers. However, its possible effects on the progression and drug resistance of BCa are still unclear. In this study, we found CHMP4C was highly expressed in BCa tissues and promoted cell proliferation. In addition, CHMP4C promoted resistance of BCa cells to Dox through targeting Snail. We further found that knockdown of CHMP4C inhibited tumor growth and enhanced sensitivity to Dox in vivo. We therefore thought CHMP4C could serve as a target for decreasing BCa drug resistance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kim YJ, Jang SK, Kim G, Hong SE, Park CS, Seong MK, et al. Nebivolol sensitizes BT-474 breast cancer cells to FGFR inhibitors. Anticancer Res. 2023;43:1973–80.
Yamanaka T, Oshima T, Murayama D, Okamoto S, Matsui AI, Yasukawa M, et al. Clinical significance of cancer stem cell markers in primary and metastatic tissues in patients with breast cancer. Anticancer Res. 2023;43:2145–54.
Das CK, Linder B, Bonn F, Rothweiler F, Dikic I, Michaelis M, et al. BAG3 overexpression and cytoprotective autophagy mediate apoptosis resistance in chemoresistant breast cancer cells. Neoplasia. 2018;20:263–79.
Liu H, Yan R, Xiao Z, Huang X, Yao J, Liu J, et al. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling. Breast Cancer Res. 2023;25:43.
Wei X, Yang M. Cell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy. Front Pharmacol. 2023;14:1180794.
Zaib S, Tahir S, Masood N, Hameed A, Azra Y. A meta-analysis and experimental data for multidrug resistance genes in breast cancer. Afr Health Sci. 2022;22:1–9.
Li J. Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer. BMC Cancer. 2023;23:353.
Lin SL, Wang M, Cao QQ, Li Q. Chromatin modified protein 4C (CHMP4C) facilitates the malignant development of cervical cancer cells. FEBS Open Bio. 2020;10:1295–303.
Carlton JG, Caballe A, Agromayor M, Kloc M, Martin-Serrano J. ESCRT-III governs the Aurora B-mediated abscission checkpoint through CHMP4C. Science. 2012;336:220–5.
Petsalaki E, Dandoulaki M, Zachos G. The ESCRT protein Chmp4c regulates mitotic spindle checkpoint signaling. J Cell Biol. 2018;217:861–76.
Petsalaki E, Zachos G. CHMP4C: a novel regulator of the mitotic spindle checkpoint. Mol Cell Oncol. 2018;5:e1445944.
Chen Y, Liu Y, Wang M. Identification of a pyroptosis-related gene signature and effect of silencing the CHMP4C and CASP4 in pancreatic adenocarcinoma. Int J Gen Med. 2022;15:3199–213.
Liu B, Guo S, Li GH, Liu Y, Liu XZ, Yue JB, et al. CHMP4C regulates lung squamous carcinogenesis and progression through cell cycle pathway. J Thorac Dis. 2021;13:4762–74.
Li K, Liu J, Tian M, Gao G, Qi X, Pan Y, et al. CHMP4C disruption sensitizes the human lung cancer cells to irradiation. Int J Mol Sci. 2015;17.
Xu S, Li X, Li W, Ma N, Ma H, Cui J, et al. Sufentanil combined with parecoxib sodium inhibits proliferation and metastasis of HER2-positive breast cancer cells and regulates epithelial-mesenchymal transition. Clin Exp Metastasis. 2023;40:149–60.
Azadeh M, Salehzadeh A, Ghaedi K, Talesh Sasani S. NEAT1 can be a diagnostic biomarker in the breast cancer and gastric cancer patients by targeting XIST, hsa-miR-612, and MTRNR2L8: integrated RNA targetome interaction and experimental expression analysis. Genes Environ. 2022;44:16.
Camilloni A, Nati G, Maggiolini P, Romanelli A, Latina R. Chronic non-cancer pain in primary care: an Italian cross-sectional study. Signa Vitae. 2021;7:54–62.
Dai R, Peng X, Lin B, Xu D, Lv R. NIR II luminescence imaging for sentinel lymph node and enhanced chemo-/photothermal therapy for breast cancer. Bioconjugate Chem. 2021;32:2117–27.
Petsalaki E, Dandoulaki M, Zachos G. Chmp4c is required for stable kinetochore-microtubule attachments. Chromosoma. 2018;127:461–73.
Casares-Arias J, Gonzalez MU, San Paulo A, Ventimiglia LN, Sadler JBA, Miguez DG, et al. Midbody remnant inheritance is regulated by the ESCRT subunit CHMP4C. iScience. 2020;23:101244.
Yang XX, Ma M, Sang MX, Zhang XY, Zou NY, Zhu SC. Knockdown of FAM83D enhances radiosensitivity in coordination with irradiation by inhibiting EMT via the Akt/GSK-3beta/Snail signaling pathway in human esophageal cancer cells. OncoTargets Ther. 2020;13:4665–78.
Huang Y, Guo Y, Xu Y, Liu F, Dai S. Flotillin-1 promotes EMT of gastric cancer via stabilizing Snail. PeerJ. 2022;10:e13901.
Gao Y, Xiang D, Li W, Zheng X, Wang L, Li Z, et al. BRAF(V600E) mutation-responsive miRNA-222-3p promotes metastasis of papillary thyroid cancer cells via snail-induced EMT. Front Endocrinol. 2022;13:843334.
Wang WD, Shang Y, Li Y, Chen SZ. Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation. Acta Pharm Sin. 2019;40:1219–27.
Mezencev R, Matyunina LV, Jabbari N, McDonald JF. Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity. BMC Cancer. 2016;16:236.
Funding
This work was supported by the Technology Research Projects of the Science Technology Department of Taizhou City (Grant No. 20ywa38).
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation and experiments were performed by XJ. Data collection and analysis were performed by JW, ZW and WP. The first draft of the manuscript was written by CY and LY and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethics approval
Ethical approval was obtained from the Ethics Committee of Taizhou Municipal Hospital.
Informed consent
Written informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Jin, X., Wang, J., Wang, Z. et al. Chromatin-modifying protein 4C (CHMP4C) affects breast cancer cell growth and doxorubicin resistance as a potential breast cancer therapeutic target. J Antibiot 77, 93–101 (2024). https://doi.org/10.1038/s41429-023-00683-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41429-023-00683-2